Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults

Completed · Not applicable

Conditions studied: Healthy Volunteers

In brief

The purpose of this study is to evaluate the concurrent validity between the Brain Performance Test (BPT) subtests and corresponding conventional in-person neuropsychological assessments (NP).

Key facts

Study ID

NCT02518204

Run by

Lumos Labs, Inc.

People needed

229

Starts

2015-07-01

Expected to finish

2017-02-28

Last updated by the study team

2017-05-25

Who can join

Age: 70 and older, up to 89. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Native English speaker
• Capable and willing to provide informed consent
• Able to use a computer and mouse without assistance
• Limited (< 3 days) or no experience with Lumosity.com
• Limited (< 3 days) or no experience with other cognitive training programs (e.g., FitBrains, CogMed)
• Willing to refrain from online cognitive training during the course of the study
• No recent (<1 years) experience with either computer-based or in-person neuropsychological tests (e.g., WAIS-IV, WISC, Halstead-Reitan Battery, MATRICS, CogState, CNS Vital Signs)
• Good general health assessed via self-reported online physical questionnaire and medical history questionnaire

You may not qualify if…

• Illiterate or unable to understand written English sufficiently to comprehend study instructions and consent form
• Uncorrected visual impairment (beyond that required to qualify for a California Driver's License) that may impact the ability to complete assessments (self-report or determined by the clinician)
• Uncorrected auditory impairment that may impact the ability to complete assessments (self-report or determined by the clinician)
• Self-reported clinical diagnosis for primary psychiatric or neurological disorder (e.g., schizophrenia, multiple sclerosis, attention deficit hyperactivity disorder, Parkinson's disease, epilepsy)
• Self-reported history of concussion or traumatic brain injury, that is considered clinically significant in the opinion of the investigator (e.g. loss of consciousness ≤ 30 minutes)
• Self-reported diagnosis of mental retardation or pervasive developmental disorder
• Self-reported diagnosis of Mild Cognitive Impairment, Alzheimer's disease, or other dementia
• Self-reported history of sustained substance or alcohol abuse or dependence, that is considered clinically significant in the opinion of the investigator (e.g. as defined by DSM-5)
• Self-report that subject is currently taking an antipsychotic, antidepressant, anti-anxiety, or a cognitively-enhancing medication (e.g. Ritalin), or in the last 72 hours, narcotics for pain or other medications that may impact cognitive performance (e.g. sleeping medications/aides or cold/allergy medications)
• Any other significant medical condition that could impact cognitive performance or result in cognitive impairment in the opinion of the investigator
• Score <28 on the MMSE
• Positive urine test for recent substance use on either testing day
• Breath Alcohol Content of 0.01% or greater on either testing day

Where it is running

• Orange County Research Center — Garden Grove, California, United States
• Northern California Research Center — Oakland, California, United States
• South Bay Research Center — Torrance, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.